Polpharma Fully Integrates Bioceros

In 2016, Polpharma Biologics acquired Dutch based Bioceros and their proprietary cell line development platform CHOBC, as well as their discovery, process development and analytical capabilities. Now, Polpharma Biologics is integrating Bioceros’ Utrecht site and their advanced cell line development capabilities fully into an extensive biologics development and manufacturing offering, and retiring the Bioceros name. This change makes Polpharma Biologics a truly integrated CDMO, offering the complete spectrum of services from discovery to commercial supply.

The step is significant for Polpharma Biologics because Bioceros’ cell line development platform offers comprehensive services for both the development of novel biologics and biosimilars. 

Polpharma Biologics have also now brought their large-scale manufacturing plant in Warsaw fully under their brand. The site—which is now in the final stages of completion—will initially add four single-use bioreactor trains offering drug substance manufacturing at 500 – 2000 L scales. This adds to their existing manufacturing capacity and will be ready for clinical and commercial supply in 2021. The site has been designed for rapid expansion of capacity when needed, with space for a further six 2000 L bioreactors.

“The full integration of Bioceros’ capabilities into Polpharma Biologics and the additional drug substance capacity soon to be available in Warsaw complements the already significant services we can provide to our clients. We can now support them from concept through development and to clinical and commercial scales,” Joerg Windisch, CEO of Polpharma Biologics, said. “Polpharma Biologics is now joining the ranks of leading CDMOs with a world-class offering to help partners take their products rapidly to market with the maximum chance of success.”